2024
DOI: 10.1097/qad.0000000000003865
|View full text |Cite
|
Sign up to set email alerts
|

Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

Chloe Orkin,
Andrea Antinori,
Jürgen K. Rockstroh
et al.

Abstract: Objective: To evaluate the efficacy and safety of 96 weeks of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment in participants switching from dolutegravir (DTG)-based therapy. Design: Studies 1489 (NCT02607930) and 1490 (NCT02607956) were phase 3 randomized, double-blind, active-controlled, first-line therapy trials in people with HIV-1. After 144 weeks of DTG-based or B/F/TAF treatment, participants could enter a 96-week open-label e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
references
References 20 publications
0
0
0
Order By: Relevance